Effect of Pramlintide on Prandial Glycemic Excursions During Closed-Loop Control in Adolescents and Young Adults With Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Even under closed-loop (CL) conditions, meal-related blood glucose (BG) excursions frequently exceed target levels as a result of delays in absorption of insulin from the subcutaneous site of infusion. We hypothesized that delaying gastric emptying with preprandial injections of pramlintide would improve postprandial glycemia by allowing a better match between carbohydrate and insulin absorptions. RESEARCH DESIGN AND METHODS: Eight subjects (4 female; age, 15–28 years; A1C, 7.5 ± 0.7%) were studied for 48 h on a CL insulin-delivery system with a proportional integral derivative algorithm with insulin feedback: 24 h on CL control alone (CL) and 24 h on CL control plus 30-μg premeal injections of pramlintide (CLP). Target glucose was set at 120 mg/dL; timing and contents of meals were identical on both study days. No premeal manual boluses were given. Differences in reference BG excursions, defined as the incremental glucose rise from premeal to peak, were compared between conditions for each meal. RESULTS: CLP was associated with overall delayed time to peak BG (2.5 ± 0.9 vs. 1.5 ± 0.5 h; P < 0.0001) and reduced magnitude of glycemic excursion (88 ± 42 vs. 113 ± 32 mg/dL; P = 0.006) compared with CL alone. Pramlintide effects on glycemic excursions were particularly evident at lunch and dinner, in association with higher premeal insulin concentrations at those mealtimes. CONCLUSIONS: Pramlintide delayed the time to peak postprandial BG and reduced the magnitude of prandial BG excursions. Beneficial effects of pramlintide on CL may in part be related to higher premeal insulin levels at lunch and dinner compared with breakfast.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Translating the A1C assay into estimated average glucose values
Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., & for the A1c-Derived Average Glucose (ADAG) Study Group (2008) · Diabetes Care · doi:10.2337/dc08-0545 · Cited by 1,812
A Bihormonal Closed-Loop Artificial Pancreas for Type 1 Diabetes
El-Khatib, F. H., Russell, S. J., Nathan, D. M., Sutherlin, R. G., & Damiano, E. R. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000619 · Cited by 403
Hollander, P. A., Levy, P., Fineman, M. S., Maggs, D. G., Shen, L. Z., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2003) · Diabetes Care · doi:10.2337/diacare.26.3.784 · Cited by 307
Ratner, R. E., Dickey, R., Fineman, M., Maggs, D. G., Shen, L., Strobel, S. A., Weyer, C., & Kolterman, O. G. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01319.x · Cited by 307
Whitehouse, F., Kruger, D. F., Fineman, M., Shen, L., Ruggles, J. A., Maggs, D. G., Weyer, C., & Kolterman, O. G. (2002) · Diabetes Care · doi:10.2337/diacare.25.4.724 · Cited by 264
Hovorka, R., Kumareswaran, K., Harris, J., Allen, J. M., Elleri, D., Xing, D., Kollman, C., Nodale, M., Murphy, H. R., Dunger, D. B., et al. (2011) · BMJ · doi:10.1136/bmj.d1855 · Cited by 244
Novel Use of Glucagon in a Closed-Loop System for Prevention of Hypoglycemia in Type 1 Diabetes
Castle, J. R., Engle, J. M., Youssef, J. E., Massoud, R. G., Yuen, K. C. J., Kagan, R., & Ward, W. K. (2010) · Diabetes Care · doi:10.2337/dc09-2254 · Cited by 232
Kovatchev, B., Cobelli, C., Renard, E., Anderson, S., Breton, M., Patek, S., Clarke, W., Bruttomesso, D., Maran, A., Costa, S., et al. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400611 · Cited by 200
Edelman, S., Garg, S., Frias, J., Maggs, D., Wang, Y., Zhang, B., Strobel, S., Lutz, K., & Kolterman, O. (2006) · Diabetes Care · doi:10.2337/dc06-0042 · Cited by 166
Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM
Kong, M.-F., King, P., Macdonald, I. A., Stubbs, T. A., Perkins, A. C., Blackshaw, P. E., Moyses, C., & Tattersall, R. B. (1997) · Diabetologia · doi:10.1007/s001250050646 · Cited by 131
Cited by
Outpatient Glycemic Control with a Bionic Pancreas in Type 1 Diabetes
Russell, S. J., El-Khatib, F. H., Sinha, M., Magyar, K. L., McKeon, K., Goergen, L. G., Balliro, C., Hillard, M. A., Nathan, D. M., & Damiano, E. R. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314474 · Cited by 602
The New Biology and Pharmacology of Glucagon
Müller, T. D., Finan, B., Clemmensen, C., DiMarchi, R. D., & Tschöp, M. H. (2017) · Physiological Reviews · doi:10.1152/physrev.00025.2016 · Cited by 419
“In line with amylin’s role in regulating glucose metabolism, the amylin analog pramlintide improves glycemic control in patients with type 1 diabetes (275, 579, 626) and type 2 diabetes (510, 578) via delaying gastric emptying (360, 361) and inhibition of postprandial glucagon secretion (385, 460).”
BackgroundAmylin: Pharmacology, Physiology, and Clinical Potential
Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G., & Roth, J. D. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010629 · Cited by 400
Closed-Loop Artificial Pancreas Systems: Engineering the Algorithms
Doyle, F. J., Huyett, L. M., Lee, J. B., Zisser, H. C., & Dassau, E. (2014) · Diabetes Care · doi:10.2337/dc13-2108 · Cited by 394
Diagnosis and management of pancreatic cystic neoplasms: current evidence and guidelines
van Huijgevoort, N. C. M., del Chiaro, M., Wolfgang, C. L., van Hooft, J. E., & Besselink, M. G. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0195-x · Cited by 263
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
Coming of age: the artificial pancreas for type 1 diabetes
Thabit, H., & Hovorka, R. (2016) · Diabetologia · doi:10.1007/s00125-016-4022-4 · Cited by 223
“A small study compared closed-loop insulin delivery either alone or with subcutaneous pramlintide before meals, during two 24 h periods [89].”
BackgroundAnti-obesity therapy: from rainbow pills to polyagonists
Müller, T. D., Clemmensen, C., Finan, B., DiMarchi, R. D., & Tschöp, M. H. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014803 · Cited by 199
ISPAD Clinical Practice Consensus Guidelines 2018: diabetes technologies
Sherr, J. L., Tauschmann, M., Battelino, T., de Bock, M., Forlenza, G., Roman, R., Hood, K. K., & Maahs, D. M. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12731 · Cited by 197
Self-citationSherr, J. L., Cengiz, E., Palerm, C. C., Clark, B., Kurtz, N., Roy, A., Carria, L., Cantwell, M., Tamborlane, W. V., & Weinzimer, S. A. (2013) · Diabetes Care · doi:10.2337/dc13-0010 · Cited by 125
“Details regarding the algorithm parameters and calibration procedures have previously been reported (21).”
BackgroundSelf-citationGingras, V., Taleb, N., Roy‐Fleming, A., Legault, L., & Rabasa‐Lhoret, R. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13052 · Cited by 113
“Two studies have so far tested pre-meal pramlintide (Amylin analog) injections against single-hormone CLS control without insulin boluses or meal announcement, showing reductions in time to peak postprandial BG and its excursion as well as in insulin doses administered by CLS post meals.(39,106) In combined insulin/pr…”
Harvey, R. A., Dassau, E., Zisser, H., Seborg, D. E., & Doyle, F. J. (2014) · Journal of Diabetes Science and Technology · doi:10.1177/1932296814523881 · Cited by 68
Qiao, Y.-C., Ling, W., Pan, Y.-H., Chen, Y.-L., Zhou, D., Huang, Y.-M., Zhang, X.-X., & Zhao, H.-L. (2017) · Oncotarget · doi:10.18632/oncotarget.16008 · Cited by 54
A Review of the Treatment of Type 2 Diabetes in Children
Onge, E. S., Miller, S. A., Motycka, C., & DeBerry, A. (2015) · The Journal of Pediatric Pharmacology and Therapeutics · doi:10.5863/1551-6776-20.1.4 · Cited by 44
Sherr, J. L., Palau Collazo, M., Cengiz, E., Michaud, C., Carria, L., Steffen, A. T., Weyman, K., Zgorski, M., Tichy, E., Tamborlane, W. V., et al. (2014) · Diabetes Care · doi:10.2337/dc13-1608 · Cited by 35
Self-citationEffect of Afrezza on Glucose Dynamics During HCL Treatment
Galderisi, A., Cohen, N., Calhoun, P., Kraemer, K., Breton, M., Weinzimer, S., & Cengiz, E. (2020) · Diabetes Care · doi:10.2337/dc20-0091 · Cited by 32
“Theadjunctiveuseof an SC injectionofpramlintideatmeal time, a synthetic analog of the peptide amylin, has been shown to reduce postprandial hyperglycemia by slowing gastric emptying and suppressing glucagon secretion (7,10).”
BackgroundSelf-citationPramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes
Galderisi, A., Sherr, J., VanName, M., Carria, L., Zgorski, M., Tichy, E., Weyman, K., Cengiz, E., Weinzimer, S., & Tamborlane, W. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-02265 · Cited by 25
Self-citation
Metadata
- Authors
- Weinzimer, S. A., Sherr, J. L., Cengiz, E., Kim, G., Ruiz, J. L., Carria, L., Voskanyan, G., Roy, A., & Tamborlane, W. V.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-09-11
- Volume
- 35
- Issue
- 10
- Pages
- 1994-1999
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1988037127
- Cited by
- 134
- References
- 13
- FWCI
- 10.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.